Erratum to: Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months (Ophthalmology and Therapy, (2016), 5, 2, (161-172), 10.1007/s40123-016-0065-3);Newly Diagnosed Primary Open-Angle Glaucoma Randomized to 2 Trabecular Bypass Stents or Prostaglandin: Outcomes Through 36 Months

Ophthalmology and Therapy

Volumn 5, Issue 2, 2016, Pages 161-172

  Vold, Steven D ^a   Voskanyan, Lilit ^b   Tetz, Manfred ^c   Auffarth, Gerd ^d   Masood, Imran ^e   Au, Leon ^f   Ahmed, Iqbal Ike K ^g   Saheb, Hady ^h  

^a Vold Vision PLLC   (United States)

^b SVMalayan's Ophthalmologic Center   (Armenia)

^c Berlin Eye Research Institute   (Germany)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e CITY HOSPITAL   (United Kingdom)

^f MANCHESTER ROYAL EYE HOSPITAL   (United Kingdom)

^g UNIVERSITY OF TORONTO   (Canada)

^h MCGILL UNIVERSITY   (Canada)

Author keywords

Glaucoma; IOP; MIGS; POAG; Prostaglandin; Trabecular bypass

Indexed keywords

PROSTAGLANDIN; TRAVOPROST;

ADULT; ARTICLE; CORNEA THICKNESS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCREENING TEST; VASCULAR DISEASE;

EID: 85066351008     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-016-0068-0     Document Type: Erratum

References (36)

1. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11 Suppl):S30–6.
2. Newman-Casey PA, Robin AL, Blachley T, et al. The most common barriers to glaucoma medication adherence: a cross-sectional survey. Ophthalmology. 2015;122:1308–16.
3. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137:3–12.
4. Nordstrom BL, Friedman DS, Mozaffari E, et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol. 2005;140:598–606.
5. Friedman DS, Quigley HA, Gelb L, et al. Using pharmacy claims data to study adherence to glaucoma medications: methodology and findings of the Glaucoma Adherence and Persistency Study (GAPS). Invest Ophthalmol Vis Sci. 2007;48:5052–7.
6. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open angle glaucoma suspects. Am J Ophthalmol. 2004;137:S13–6.
7. Mansberger SL. Are you compliant with addressing glaucoma adherence? Am J Ophthalmol. 2010;149(1):1.
8. Nagar M, Ogunyomade A, O’Brart DP, et al. A randomised, prospective study comparing selective laser trabeculoplasty with latanoprost for the control of intraocular pressure in ocular hypertension and open angle glaucoma. Br J Ophthalmol. 2005;89:1413–7.
9. Saheb H, Ahmed II. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol. 2012;23:96–104.
10. Regulatory Affairs Division, Glaukos Corporation, Laguna Hills, CA, USA. Data on file.
11. Fea AM. Phacoemulsification versus phacoemulsification with micro-bypass stent implantation in primary open-angle glaucoma. J Cataract Refract Surg. 2010;36:407–12.
12. Samuelson TW, Katz LJ, Wells JM, Duh Y-J, Giamporcaro JE. Randomized evaluation of the trabecular micro-bypass stent with phacoemulsification in patients with glaucoma and cataract. Ophthalmology. 2011;118:459–67.
13. Craven ER, Katz LJ, Wells JM, Giamporcaro JE. Cataract surgery with trabecular micro-bypass stent implantation in patients with mild-to-moderate open-angle glaucoma and cataract: two-year follow-up. J Cataract Refract Surg. 2012;38:1339–45.
14. Arriola-Villalobos P, Martinez-de-la-Casa J, Diaz-Valle D, et al. Combined iStent trabecular micro-bypass stent implantation and phacoemulsification for coexistent open-angle glaucoma and cataract: a long-term study. Br J Ophthalmol. 2012;96:645–9.
15. Neuhann TH. Trabecular micro-bypass stent implantation during small-incision cataract surgery for open-angle glaucoma ocular hypertension: long-term results. J Cataract Refract Surg. 2015;41:2664–71.
16. Fea AM, Consolandi G, Zola M, et al. Micro-bypass implantation for primary open-angle glaucoma combined with phacoemulsification: 4-year follow-up. J Ophthalmol. 2015. Article ID 795357. http://dx.doi.org/10.1155/2015/795357. Accessed July 12, 2016.
17. Spiegel D, Wetzel W, Neuhann T, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol. 2009;19:393–9.
18. Belovay GW, Naqi A, Chan BJ, Rateb M, Ahmed II. Using multiple trabecular micro-bypass stents in cataract patients to treat open-angle glaucoma. J Cataract Refract Surg. 2012;38(11):1911–7.
19. Ahmed II, Katz LJ, Chang DF, et al. Prospective evaluation of microinvasive glaucoma surgery with trabecular microbypass stents and prostaglandin in open-angle glaucoma. J Cataract Refract Surg. 2014;40:1295–300.
20. Donnenfeld ED, Solomon KD, Voskanyan L, et al. A prospective 3-year follow-up trial of implantation of two trabecular microbypass stents in open-angle glaucoma. Clin Ophthalmol. 2015;9:2057–65.
21. Katz LJ, Erb C, Carceller Guillamet AC, et al. Prospective, randomized study of one, two, or three trabecular bypass stents in open-angle glaucoma subjects on topical hypotensive medication. Clin Ophthalmol. 2015;9:2313–20.
22. Rulli E, Biagioli E, Riva I, et al. Efficacy and safety of trabeculectomy vs nonpenetrating surgical procedures. A systematic review and meta-analysis. JAMA Ophthalmol. 2013;131:1573–82.
23. Höh H, Grisanti S, Grisanti S, Rau M, Ianchulev S. Two-year clinical experience with the CyPass micro-stent: safety and surgical outcomes of a novel supraciliary micro-stent. Klin Monbl Augenheilkd. 2014;231(4):377–81.
24. Sarkisian S. Combined cataract surgery and supraciliary microstent implantation for open-angle glaucoma: multicenter 3-year results. Presented at 2016 American Society of Cataract and Refractive Surgeons, May, 2016, New Orleans, LA, USA.
25. Vold S. Prospective, randomized evaluation of microinvasive glaucoma surgery (MIGS) with two trabecular microbypass stents vs. prostaglandin in open-angle or pseudoexfoliative glaucoma or ocular hypertension naïve to therapy. Poster presented at 2015 Annual Meeting of the American Glaucoma Society, February 26—March 1, 2015, Coronado, CA.
26. http://www.clintrials.gov. Accessed July 20, 2016.
27. Terminology and guidelines for glaucoma. ISBN 978-88-98320-05-09. Copyright 2014 European Glaucoma Society. http://www.eugs.org. Accessed July 22, 2016.
28. Okeke CO, Quigley HA, Jampel HD, et al. Adherence with topical glaucoma medication monitored electronically. The Travatan dosing aid study. Ophthalmology. 2009;116:191–9.
29. Robin AL, Novack GD, Covert DW, et al. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533–40.
30. Tsai JC. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116:S30–6.
31. Red Book ™. Ann Arbor: Truven Health Analytics; 2013. http://micromedex.com/products/product-suites/clinical-knowledge/redbook. Accessed July 6, 2016.
32. Salim S, Shields MB. Glaucoma and systemic diseases. Surv Ophthalmol. 2010;55:64–77.
33. Peace J, Ahlberg P, Wagner M, et al. Equivalent IOP lowering found when travoprost is preserved with polyquaternium or benzalkonium chloride. Am J Ophthalmol. 2015;160:266–74.
34. Parrish RK, Palmberg P, Sheu W-P, XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol. 2003;135:688–703.
35. Lanzl I, Hamacher T, Rosbach K, et al. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clin Ophthalmol. 2013;7:901–10.
36. Brown RH, Gibson Z, Zhong L, Lynch MG. Intraocular pressure reduction after cataract surgery with implantation of a trabecular microbypass device. J Cataract Refract Surg. 2015;41(6):1318–9.